EureKING planning creation of new biotech company through the acquisition of SCTbio

August 9, 2023
Business Services, Research and Development Pharmacy

On 9 August 2023, eureKING announced it is set to acquire the pharmaceutical company SCTbio which specializes in cell and …

heartbeat

Novo Nordisk’s Wegovy reduces risk of cardiovascular events

August 9, 2023
Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide

Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …

Oculis announces positive results from phase 3 OPTIMIZE trial

August 9, 2023
Research and Development Oculis, Opthalmology, clinical trial, eyedrops, ocular surgery

Oculis has announced positive topline results from its phase 3 OPTIMIZE trial for its OCS-01 eyedrops, a once daily, high …

FDA grants clearance to next phase of Ascentage Pharma’s clinical trial for CLL/SLL treatment

August 8, 2023
Research and Development Ascentage Pharma, CLL/SLL, FDA, Oncology, clinical trial

Ascentage Pharma has announced that the US Food and Drug Administration (FDA) has granted clearance for the phase 3 study …

Astex expands collaboration with MSD

August 8, 2023
Business Services Astex pharmaceuticals, Merck, Oncology, collaboration, small molecules

Astex Pharmaceuticals has announced an exclusive worldwide research collaboration and license agreement with MSD (known as Merck in the US), …

Amarin’s Vazkepa accepted by SMC for patients with cardiovascular disease

August 8, 2023
Research and Development Cardiology, Vazkepa, cardiovascular disease, pharmaceutical

On 7 August 2023, the Scottish Medicines Consortium (SMC) announced that they had accepted Amarin’s treatment for people with cardiovascular …

First oral treatment for women with postpartum depression approved by FDA

August 7, 2023
Research and Development FDA, postpartum depression, treatment, zurzuvae

On 4 August 2023, the US Food and Drug Administration (FDA) approved the use of Zurzuvae for adults with postpartum …

Vaccine image

New vaccine research centre opened to prepare for future pandemics

August 7, 2023
Research and Development Immunology, UKHSA, pandemic, vaccine research centre

Ministers have opened a new vaccine research centre at the UK Health and Security Agency’s (UKHSA) Porton Down campus in …

eye2

Astellas announces FDA approval for Izervay for GA treatment

August 7, 2023
Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy

Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …

FDA approves Merck’s Ervebo vaccine for under 18s

August 4, 2023
Research and Development FDA, Immunology, Vaccine, ebolavirus

On 3 August 2023, the US Food and Drug Administration (FDA) approved Merck’s Ervebo vaccine for children over 12 months. …

Evox Therapeutics enters agreement for next generation gene therapy for heart disease

August 4, 2023
Research and Development Cardiology, Evox Therapeutics, Icahn Mount Sinai, cvd, gene therapy

Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn …

Ionis and Novartis partner for CVD treatment programme

August 4, 2023
Business Services Cardiology, Ionis Pharmaceuticals, License Agreement, Novartis, cvd

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement with Novartis, aiming to discover, …

Targeted chemotherapy to kill all solid tumours developed in preclinical research

August 3, 2023
Research and Development Cancer, Oncology, chemotherapy, pharmaceutical, tumour

Researchers from the City of Hope organisation in the US have released a study confirming the development of AOH1996, a …

FDA approves Taiho’s Lonsurf for metastatic colorectal cancer treatment

August 3, 2023
Medical Communications FDA, Lonsurf, Oncology, colorectal cancer, mCRC, taiho

Taiho Oncology and Taiho Pharmaceutical have announced that the US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil) as …

Chemotherapy

FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma

August 3, 2023
Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma

ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …

Biopharmaceutical company EQRx set to be acquired by Revolution Medicines

August 2, 2023
Research and Development EQRx, Pharmacy, biopharmaceutical, pharmaceutical, revolution medicines

On 1 August 2023, Revolution Medicines signed an official agreement confirming the acquisition of the biopharmaceutical company EQRx. The deal …

brainss

Proof-of-concept study shows non-invasive brain stimulation efficient as treatment for ADHD in children

August 2, 2023
Research and Development ADHD, Hebrew University of Jerusalem, Psychiatry, brain stimulation, clinical trial, university of surrey

Researchers from the University of Surrey, UK, and the Hebrew University of Jerusalem, Israel, have found that non-invasive brain stimulation …

MyMD reports statistically significant results from phase 2 trial for sarcopenia/age-related frailty

August 2, 2023
Research and Development Musculo-skeletal disorder, MyMD, clinical trial, sarcopenia

MyMD Pharmaceuticals has announced statistically significant positive topline results from a phase 2 trial of oral TNF- α inhibitor, MYMD-1 …

The NIH’s RECOVER initiative could lead to the first official treatment for long COVID-19

August 1, 2023
Research and Development COVID-19, Infections and infestations, NIH, clinical trials, long covid

As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials of its ‘Researching COVID to …

cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

Merck shares data from phase 3 trial for breast cancer treatment

August 1, 2023
Research and Development MSD, Merck, Oncology, breast cancer, keytruda

Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …

The Gateway to Local Adoption Series

Latest content